Salvage haploidentical or cord-blood allogeneic stem cell transplantation after a prior alternative allograft in hematologic malignancies: a retrospective study from the SFGM-TC.

Fiche publication

Date publication

septembre 2022

Journal

European journal of haematology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERCEANU Ana , Pr RUBIO Marie Thérèse

Tous les auteurs :
Cavalieri D, Rubio MT, Corriger A, Pereira B, Cabrespine A, Robin M, Labussière-Wallet H, Calleja A, Forcade E, Chevallier P, Guillerm G, Berceanu A, Bulabois CE, Maillard N, Nguyen S, Raus N, Schoemans H, Bay JO, Ravinet A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36151965

Résumé

Haploidentical (haplo-) donors and cord-blood (CB) stem cells provide alternative transplant options in patients lacking an HLA-matched donor. In case of relapse or graft failure after a first alternative allogeneic hematopoietic stem cell transplant (HSCT), a second alternative HSCT (HSCT2) is rarely considered due to a high risk of toxicity.